Champions Oncology (NASDAQ:CSBR – Get Free Report) and Charles River Laboratories International (NYSE:CRL – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Insider & Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 46.4% of Champions Oncology shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Champions Oncology and Charles River Laboratories International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.87% | -27.48% | -3.84% |
| Charles River Laboratories International | -5.96% | 15.75% | 6.51% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $59.42 million | 1.16 | -$1.17 million | ($0.08) | -62.04 |
| Charles River Laboratories International | $4.02 billion | 3.55 | -$144.34 million | ($4.85) | -61.60 |
Champions Oncology has higher earnings, but lower revenue than Charles River Laboratories International. Champions Oncology is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Champions Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Champions Oncology and Charles River Laboratories International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Charles River Laboratories International | 1 | 3 | 12 | 0 | 2.69 |
Charles River Laboratories International has a consensus price target of $255.65, suggesting a potential downside of 14.43%. Given Charles River Laboratories International’s stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Champions Oncology.
Summary
Charles River Laboratories International beats Champions Oncology on 10 of the 14 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
About Charles River Laboratories International
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
